Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707534 · ClinicalTrials.gov registry record · Phase 4
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
A Phase 4 study of COVID-19, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT04707534: Completed Phase 4 study of COVID-19, sponsored by University of Oklahoma.
NCT04707534 is a Phase 4 study of COVID-19 that has completed, run by University of Oklahoma. The registered enrollment target is 110 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04707534, a Phase 4 study of COVID-19, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
Primary Outcome
the clinical improvement of greater than or equal to 2 points using the WHO-OSCI. 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen by mask or nasal prongs 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation 7. Hospitalized, on invasive mechanical ventilation + additional organ supp
Conditions Studied
Interventions
- DRUG Dexamethasone
Study Locations (1)
Oklahoma
- University of Oklahoma Medical Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2022-03-04 |
| Phase | Phase 4 |
What the finished NCT04707534 record still lists
NCT04707534 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Dexamethasone is the first listed.
NCT04707534 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04707534 about?
NCT04707534 is a clinical study titled "Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19". This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
What is the current status of trial NCT04707534?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2021-01-21. Estimated completion is 2022-03-04.
What conditions does trial NCT04707534 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04707534?
The interventions under investigation include: Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT04707534?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04707534 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04707534's enrollment target sits among peer trials
110 194th of 298 higher than 105 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI